Kinnate Biopharma

Kinnate Biopharma

  • Founded: 2018
  • Location: San Diego, CA
  • Employee range: 50 - 200
  • Clinical stage: Clin1b
  • Therapy area: Solid tumors, melanoma
  • Drug types: ONC
  • Lead product: Exarafenib
  • Product link:
  • Funding: $276M IPO Dec 2020; $98M C Aug 2020; $74.5M B Dec 2019

job board

Short description:

Small Molecules

Drug notes:

Also Clin1a melanoma; KIN-3248 Clin1a solid tumors; KIN-7136 Clin0 solid tumors; KIN-8741 Clin0 solid tumors; KIN004 RD solid tumors

Long description:

Kinnate Biopharma is designing and developing selective small molecules to target various cancers. Kinases are a class of proteins that are effective targeting nodes in cancer, but have been hard to target selectively with drugs. Kinate is using structure-based drug discovery and translational research to design molecules with high selectivity, optimized pharmaceutical properties, broad coverage of genetic alterations for different genetic changes in cancer cells, and the ability to overcome resistance or penetrate the brain. Using this stringent drug selection approach, with their well-defined patient populations, Kinnate hopes to streamline the development process and increase their chances of success.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy